durvalumab ± tremelimumab

**Durvalumab ± tremelimumab** is not a single chemical entity or a fixed-dose branded product; it is a trial/regimen shorthand referring to **durvalumab alone** or **durvalumab plus tremelimumab**. Durvalumab is a human IgG1 monoclonal antibody that binds programmed death-ligand 1 and prevents its inhibitory interaction with PD-1 and CD80, whereas tremelimumab is a human IgG2 monoclonal antibody that blocks cytotoxic T-lymphocyte-associated antigen 4. Together, dual checkpoint blockade is intended to enhance antitumor T-cell activity through complementary PD-L1 and CTLA-4 pathway inhibition. AstraZeneca developed both agents. The durvalumab-tremelimumab regimen is FDA-approved, with other required therapies, for unresectable hepatocellular carcinoma and metastatic non-small cell lung cancer; the exact ± notation also encompasses durvalumab-only arms used across other approved and investigational settings. ([fda.gov](https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-tremelimumab-combination-durvalumab-unresectable-hepatocellular-carcinoma))

Other names

durvalumab with or without tremelimumab